An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

ConditionInflammation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-79
SponsorQualia Life Sciences

About this trial

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

Eligibility criteria

Qualifiers

Provide voluntary, written, informed consent to participate in the study

Agree to provide a valid cell phone number and are willing to receive communications through text.

Healthy adults 45 - 79 years of age Can read and write English

Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.

Disqualifiers

Women who are pregnant, breastfeeding, or planning to become pregnant during the trial

Known food intolerances/allergy to any ingredients in the product

Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer

Having had a significant cardiovascular event in the past 6 months

Trial design

Treatments tested in this trial

  • Qualia Senolytic

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators